Blog Archive

Sunday, August 28, 2016

Learn About the History of Two Prolonged Half-life Therapies

We’ve been focusing on changing therapies in the hemophilia community the past two years, including products that give us more options and choices. Read below to learn about how Biogen scientists developed two products that are being used to help improve hemophilia care.

Please see below for the Indications and Important Safety Information

In 2000, Rob Peters and Jenny Dumont, currently top scientists at Biogen, wanted to make a difference in hemophilia care. They saw that hemophilia therapy hadn’t changed since the 1970s and there was an unmet need for a new class of treatment.

Rob, Jenny, and their team knew it wouldn’t be easy. They were fully aware that it often takes years, even decades, to get a therapy from that spark of inspiration through research, clinical trials, and FDA approval to the community who so eagerly wanted an alternative therapy.

Rob has a PhD in biochemistry from Harvard and is a VP, Hematology Research, at Biogen. Jenny has her PhD in cell biology from the University of Cincinnati College of Medicine and is the Medical/Scientific Director, Global Medical, at Biogen. Both certainly had the education and training to tackle such a daunting challenge. More importantly, Rob and Jenny had an unwavering passion to develop new therapies.

Their passion helped them stick with it and in 2014, after a decade and a half of hard work and determination, Biogen launched prolonged half-life ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX®  [Coagulation Factor IX (Recombinant), Fc Fusion Protein].

Prolonged half-life ELOCTATE and ALPROLIX have been helping people with hemophilia for the past two years. In that time, doctors have written thousands of prescriptions.

Rob and Jenny recently returned from the National Hemophilia Foundation and World Federation of Hemophilia meetings, where they had the opportunity to talk with people who have been taking ELOCTATE and ALPROLIX. They got to see, firsthand, that their perseverance and passion was well worth the effort.

“Bringing ELOCTATE and ALPROLIX from inception to the people who need them was a lot like raising children,” Jenny says. Jenny is a mother of 2 and grandmother of 3. “You give them so much of your energy and attention for so many years, then let them go into the world and hope they make an impact.”

Rob, father of eight-and-a-half-year-old twins, agrees, adding: “I was raising my twins the same time we were developing ELOCTATE/ALPROLIX. That really helped me appreciate the potential of what more time between infusions could mean in the lives of families with kids with hemophilia.”

Learn about the science behind ELOCTATE  and ALPROLIX .

ELOCTATE Indications
ELOCTATE is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.

ELOCTATE Selected Important Safety Information
Do not use ELOCTATE if you have had an allergic reaction to it in the past.


ALPROLIX Indications
ALPROLIX is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency.

Your healthcare provider may give you ALPROLIX when you have surgery.

ALPROLIX Selected Important Safety Information

Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.


This blog was sponsored by Biogen for educational purposes.

HEM-US-1198 08/16



©2016 Biogen. All rights reserved.






No comments :

 
Bayer